These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 36811949

  • 1. Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study.
    Dudink K, Bouwman K, Chen Y, DePrimo SE, Munoz-Elias EJ, Aarts P, Schappin R, Florencia EF, van Heeswijk B, Prens LM, van der Zee HH, Prens EP, van Straalen KR, Horváth B.
    Br J Dermatol; 2023 Apr 20; 188(5):601-609. PubMed ID: 36811949
    [Abstract] [Full Text] [Related]

  • 2. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, Vilarrasa E, Silvente C, Ciudad Blanco C, Romaní J, Martorell A, Fernández P, Romero Ferreiro C, Molina Leyva A.
    Actas Dermosifiliogr; 2023 Oct 20; 114(9):755-762. PubMed ID: 37331620
    [Abstract] [Full Text] [Related]

  • 3. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
    Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, Vilarrasa E, Silvente C, Ciudad Blanco C, Romaní J, Martorell A, Fernández P, Romero Ferreiro C, Molina Leyva A.
    Actas Dermosifiliogr; 2023 Oct 20; 114(9):T755-T762. PubMed ID: 37479135
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
    Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P.
    Br J Dermatol; 2024 May 17; 190(6):836-845. PubMed ID: 38470171
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
    Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C.
    J Eur Acad Dermatol Venereol; 2021 Dec 17; 35(12):2431-2439. PubMed ID: 34378812
    [Abstract] [Full Text] [Related]

  • 9. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study.
    Kimball AB, Podda M, Alavi A, Miller M, Shen YK, Li S, Xu Y, Han C, Fakharzadeh S, Yang YW, DePrimo S, Munoz E, Chen Y, Passeron T, Papp K.
    J Eur Acad Dermatol Venereol; 2023 Oct 17; 37(10):2098-2108. PubMed ID: 37317022
    [Abstract] [Full Text] [Related]

  • 10. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, Teixeira HD, Jemec GB.
    J Eur Acad Dermatol Venereol; 2016 Jun 17; 30(6):989-94. PubMed ID: 26201313
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE, Okun MM, Forman SB, Gulliver WPF, Prens EP, Mrowietz U, Armstrong AW, Geng Z, Gu Y, Williams DA, Teixeira HD, Kimball AB.
    Br J Dermatol; 2019 Nov 17; 181(5):967-975. PubMed ID: 30916379
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW, Jiang CS, Singh N, Grand D, Navrazhina K, Vaughan R, Krueger JG.
    J Am Acad Dermatol; 2020 May 17; 82(5):1150-1157. PubMed ID: 31881294
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.
    Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M.
    Br J Dermatol; 2014 Dec 17; 171(6):1434-42. PubMed ID: 25040429
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa.
    Argyropoulou M, Trigoni A, Kaffenberger J, Stergianou D, Damoraki G, Mingiani E, Micha S, Krispinsky A, Meltzanidou P, Kanni T, Lazaridou E, Giamarellos-Bourboulis EJ.
    Dermatology; 2023 Dec 17; 239(5):746-752. PubMed ID: 37331331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.